Increased concentrations of ribonuclease (RNase; EC 3.1.27.5) activity in human serum have been reported in cases of renal failure (4, 5), pancreatic cancer (6), multiple myeloma (7), leukemia (8), and other diseases (9). However, the effect of IFN therapy on RNase activity in serum has not been previously reported.
2',5'-oligoadenylate synthetase (2-5 AS; no EC no. assigned) activities in serum were measured in nine patients with hepatitisB e antigen-positivechronichepatitisB before, during, and after treatment with recombinant human interferon a-2b for fourweeks at daily doses ranging from 3 to 10 mega-units. Alkaline RNase activitiesin serum significantly increased from 65.8±9.5 units/L (mean±SD) to 84.3±11.9 units/L after the first week of therapy(P <0.001). (One unitof ANase activityis defined as that increasingthe absorbance at 260 nm by 1.0 in 1 mm.) This increase persisted during and until two weeks after the end of the therapy, at which time the mean RNase activityin serum was still significantly increased (70.8±9.4 units/L, P <0.01). Before therapy, phosphocellulosechromatographyof RNase showed five active peaks of enzyme activity,which weresimilarto that observed even when RNase activityincreased immediately after therapy. There was a close correlationbetween RNase activities and the logarithm of 2-5 AS activities, measured simultaneously in each patient. We conclude that recombinant a-interferontherapy increases RNase activitiesin serum, associated with the increased 2-5 AS activities.
The antiviral action of interferon (IFN) has been demonstrated to be mediated by activation ofendonuclease, which degrades viral messenger ribonucleic acid (RNA).' In IFNtreated cells, IFN-induced 2',5'-oligoadenylate synthetase (2-5 AS) catalyzes the synthesis of 2',5'-oligoadenylate (2-5 A) from ATP in the presenceof double-strandedRNA, and 2-5 A activates endonuclease (1) (2) (3) . Because IFN may inhibit viral replication in this way, endonucleasemay play an important role in the antiviral action of IFN. Increased concentrations of ribonuclease (RNase; EC 3.1.27.5) activity in human serum have been reported in cases of renal failure (4, 5) , pancreatic cancer (6) , multiple myeloma (7) , leukemia (8), and other diseases (9). However, the effect of IFN therapy on RNase activity in serum has not been previously reported.
Recently, recombinant human leukocyte IFN has been used for treating chronic hepatitis B virus (HBV) infection.
A variable response rate, usually seroconversion from hepatitis B e antigen (HBeAg) to antibody to HBeAg (antiHBe), and occasionally complete clearance of the virus have been reported in IFN therapy (10) (11) (12) . We therefore measured alkaline RNase activities in serum in a preliminary study of recombinant human leukocyte IFN therapy in patients with chronic hepatitis B. Here we report our findingsand discussthe possibility that serumRNase could be used for monitoring IFN therapy.
Materials and Methods
Patients. Nine Japanese male patients with chronichepatitis B were studied prospectively.All patients had been positive for hepatitis B surface antigen (HBsAg) Figure 1 (Figure 2, top) . After four weeks of therapy with a-IFN, the patient's serum still contained five peaks of activity, eluted in the same positions and with each peak increased to the same degree (Figure 2, bottom) showed normal aminotransferase activities at one month after therapy, and had no detectable HBeAg by two months after therapy. HBeAg was undetectable in serum from patient no. 8 after the first week of therapy, and aminotransferase activities were normal by two weeks after therapy. In patients no.4 and 8, anti-HBe was not detected throughout the observation period. We compared values for these three responders with those for the remaining six patients (nonresponders). The mean activity of RNase in serum was slightly higher in responders than in nonresponders before, during, and after therapy; however, this difference was not statistically significant. In contrast, the mean activity of 2-5 AS in serum from responderswas slightly lower than that from nonrespondersduring the whole observation period but, again, this difference was not significant between the two groups. Thus, we could not distinguish the responders from the nonresponders by either RNase activities or 2-5 AS activities in their sera.
Discussion
The presentstudy demonstrateda significant increase in alkaline RNase activities in serum from patients with chronic hepatitis B receiving a-IFN therapy. These increased enzyme activities returned to pretreatment values by four weeks after the end of therapy. Although the mechanismof an increase of serum RNase activity remains to be clarified, several possibilities can be proposed. Of these, impaired renal function must be considered because increased RNase activities have been observed in patients suffering from renal failure, and positive correlations between RNase and urea or creatinine concentration have been described (15) . In our patients, however, the concentrations of creatinine and urea nitrogen in serum were within normal ranges, and remained unchanged during the IFN therapy. An alternative explanation for the increase in RNase activity may be associated with the protein nutritional condition. Increased activities of RNase have also been reported in children with protein malnutrition (9) and in adult patients receiving corticosteroid, which has protein catabolic effects (16). Furthermore, Shenkin et al. (15) have described an increase in RNase in plasma associated with a decrease in albumin in serum of patients with protein deficiency and normal renal function. In the present study, the concentrations of serum albumin were not affected by therapy, although subclinical protein malnutrition could not be excluded because anorexia is commonly seen in most series evaluating therapy with human IFN (10, 12) . Results in this laboratory (14) have established the existencein normal human serum of five alkaline RNases which differ in optimal pH, molecular mass, heat stability, substrate specificity, and behavior toward metal ions. In the present study, alkaline RNase in serum was eluted as the five active fractions on phosphocellulose chromatography both before and immediately after therapy. A specific RNase indicating an increase in activity was not detected in the serum after IFN therapy.
Recently, several reports have demonstrated an increased 2-5 AS activity in peripheral mononuclearcellsand serum from patients receiving IFN therapy (17, 18). Takeda et al. (19) showed that 2-5 AS activity in peripheral mononuclear cells was induced by IFN therapy more in patients whose HBeAg had become undetectable within one year of the end of therapy than in those with sustained HBeAg. In the present study, however, disappearance of HBeAg was unassociated with the activities of serum 2-5 AS or serum RNase before, during, or after therapy.
This preliminary study of recombinant human leukocyte IFN therapy for patients with chronic hepatitis B has shown an increase in alkaline RNase activity in serum.
Although the number of patients analyzed was small, the results suggest that recombinant human a-JFN enhances RNase activities in serum through increased 2-5 AS activities. Further study will be needed to assess the exact relationship between the effects of a-IFN on ENase activities in serum and the therapeutic efficacy of a-IFN.
